Watch our webinar featuring Prof. Daniele De Luca now! During this 60 minute event, Prof. De Luca discussed the results of a controlled before-after quality improvement study, published in 2021 in the “Anesthesia, Analgesia and Critical Care” journal. 
 
This study shows that NIV-NAVA, delivered as first-line noninvasive respiratory support (NRS) in pediatric moderate AHRF of infectious origin, is associated with a lower intubation rate, shorter PICU and hospital length of stay, as well as early improvement of physiological parameters compared to NIV-PS traditional treatment including endotracheal intubation and mechanical ventilation.